Thomas C Havey1, Robert A Fowler2, Ruxandra Pinto3, Marion Elligsen4, Nick Daneman5. 1. Department of Medicine, University of Toronto, Toronto, Ontario. 2. Department of Medicine, University of Toronto, Toronto, Ontario ; Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario ; Trauma, Emergency and Critical Care Research Program, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario. 3. Trauma, Emergency and Critical Care Research Program, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario. 4. Department of Pharmacy, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario. 5. Department of Medicine, University of Toronto, Toronto, Ontario ; Trauma, Emergency and Critical Care Research Program, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario ; Division of Infectious Diseases, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario.
Abstract
BACKGROUND: The optimal duration of antibiotic treatment for bloodstream infections is unknown and understudied. METHODS: A retrospective cohort study of critically ill patients with bloodstream infections diagnosed in a tertiary care hospital between March 1, 2010 and March 31, 2011 was undertaken. The impact of patient, pathogen and infectious syndrome characteristics on selection of shorter (≤10 days) or longer (>10 days) treatment duration, and on the number of antibiotic-free days, was examined. The time profile of clinical response was evaluated over the first 14 days of treatment. Relapse, secondary infection and mortality rates were compared between those receiving shorter or longer treatment. RESULTS: Among 100 critically ill patients with bloodstream infection, the median duration of antibiotic treatment was 11 days, but was highly variable (interquartile range 4.5 to 17 days). Predictors of longer treatment (fewer antibiotic-free days) included foci with established requirements for prolonged treatment, underlying respiratory tract focus, and infection with Staphylococcus aureus or Pseudomonas species. Predictors of shorter treatment (more antibiotic-free days) included vascular catheter source and bacteremia with coagulase-negative staphylococci. Temperature improvements plateaued after the first week; white blood cell counts, multiple organ dysfunction scores and vasopressor dependence continued to decline into the second week. Among 72 patients who survived to 10 days, clinical outcomes were similar between those receiving shorter and longer treatment. CONCLUSION: Antibiotic treatment durations for patients with bloodstream infection are highly variable and often prolonged. A randomized trial is needed to determine the duration of treatment that will maximize cure while minimizing adverse consequences of antibiotics.
BACKGROUND: The optimal duration of antibiotic treatment for bloodstream infections is unknown and understudied. METHODS: A retrospective cohort study of critically illpatients with bloodstream infections diagnosed in a tertiary care hospital between March 1, 2010 and March 31, 2011 was undertaken. The impact of patient, pathogen and infectious syndrome characteristics on selection of shorter (≤10 days) or longer (>10 days) treatment duration, and on the number of antibiotic-free days, was examined. The time profile of clinical response was evaluated over the first 14 days of treatment. Relapse, secondary infection and mortality rates were compared between those receiving shorter or longer treatment. RESULTS: Among 100 critically illpatients with bloodstream infection, the median duration of antibiotic treatment was 11 days, but was highly variable (interquartile range 4.5 to 17 days). Predictors of longer treatment (fewer antibiotic-free days) included foci with established requirements for prolonged treatment, underlying respiratory tract focus, and infection with Staphylococcus aureus or Pseudomonas species. Predictors of shorter treatment (more antibiotic-free days) included vascular catheter source and bacteremia with coagulase-negative staphylococci. Temperature improvements plateaued after the first week; white blood cell counts, multiple organ dysfunction scores and vasopressor dependence continued to decline into the second week. Among 72 patients who survived to 10 days, clinical outcomes were similar between those receiving shorter and longer treatment. CONCLUSION: Antibiotic treatment durations for patients with bloodstream infection are highly variable and often prolonged. A randomized trial is needed to determine the duration of treatment that will maximize cure while minimizing adverse consequences of antibiotics.
Entities:
Keywords:
Antibacterials; Antibiotic stewardship; Bacteremia; Bacterial infections; Critical care
Authors: Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper Journal: Clin Infect Dis Date: 2011-03-01 Impact factor: 9.079
Authors: F S Nolte; J M Williams; R C Jerris; J A Morello; C D Leitch; S Matushek; L D Schwabe; F Dorigan; F E Kocka Journal: J Clin Microbiol Date: 1993-03 Impact factor: 5.948
Authors: Joseph S Solomkin; John E Mazuski; John S Bradley; Keith A Rodvold; Ellie J C Goldstein; Ellen J Baron; Patrick J O'Neill; Anthony W Chow; E Patchen Dellinger; Soumitra R Eachempati; Sherwood Gorbach; Mary Hilfiker; Addison K May; Avery B Nathens; Robert G Sawyer; John G Bartlett Journal: Clin Infect Dis Date: 2010-01-15 Impact factor: 9.079
Authors: Michelle H Scerbo; Heidi B Kaplan; Anahita Dua; Douglas B Litwin; Catherine G Ambrose; Laura J Moore; Col Clinton K Murray; Charles E Wade; John B Holcomb Journal: Surg Infect (Larchmt) Date: 2016-02-26 Impact factor: 2.150
Authors: Ilse van Langeveld; Robin C Gagnon; Peggie F Conrad; Richard L Gamelli; Brendan Martin; Mashkoor A Choudhry; Michael J Mosier Journal: J Burn Care Res Date: 2017 Mar/Apr Impact factor: 1.845
Authors: Darunee Chotiprasitsakul; Jennifer H Han; Sara E Cosgrove; Anthony D Harris; Ebbing Lautenbach; Anna T Conley; Pam Tolomeo; Jacqueleen Wise; Pranita D Tamma Journal: Clin Infect Dis Date: 2018-01-06 Impact factor: 9.079
Authors: Nick Daneman; Asgar H Rishu; Wei Xiong; Sean M Bagshaw; Deborah J Cook; Peter Dodek; Richard Hall; Anand Kumar; Francois Lamontagne; Francois Lauzier; John C Marshall; Claudio M Martin; Lauralyn McIntyre; John Muscedere; Steven Reynolds; Henry T Stelfox; Robert A Fowler Journal: Trials Date: 2015-04-18 Impact factor: 2.279
Authors: Angela Huttner; Werner C Albrich; Pierre-Yves Bochud; Angèle Gayet-Ageron; Anne Rossel; Elodie von Dach; Stephan Harbarth; Laurent Kaiser Journal: BMJ Open Date: 2017-07-13 Impact factor: 2.692
Authors: Eman Alqasim; Sameera Aljohani; Majid Alshamrani; Nick Daneman; Robert Fowler; Yaseen Arabi Journal: Ann Thorac Med Date: 2018 Jan-Mar Impact factor: 2.219
Authors: Nick Daneman; Asgar H Rishu; Ruxandra Pinto; Pierre Aslanian; Sean M Bagshaw; Alex Carignan; Emmanuel Charbonney; Bryan Coburn; Deborah J Cook; Michael E Detsky; Peter Dodek; Richard Hall; Anand Kumar; Francois Lamontagne; Francois Lauzier; John C Marshall; Claudio M Martin; Lauralyn McIntyre; John Muscedere; Steven Reynolds; Wendy Sligl; Henry T Stelfox; M Elizabeth Wilcox; Robert A Fowler Journal: Trials Date: 2018-02-17 Impact factor: 2.279